Well BARDA and now the FDA (with full randomized trials) believes ReCell works.
I am not saying BTM doesn't work, what I am saying is that it will be difficult for PNV management to convince surgeons to use BTM without the full randomized trials. Yes, I am aware that BTM has the easier FDA 510k approval and I understand that BARDA is supporting BTM and will finance full randomized, but that is some time away, probably 2 to 5 years away.
Polynovo Channel 7, page-10
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.07 |
Change
0.030(1.47%) |
Mkt cap ! $1.429B | |||
| Open | High | Low | Value | Volume |
| $2.11 | $2.12 | $2.05 | $2.783M | 1.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 19976 | $2.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.07 | 9633 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |